Giulio Sartori
A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers.
Spriano F, Sartori G, Sgrignani J, Barnabei L, Arribas A, Guala M, Del Amor A, Tomasso M, Tarantelli C, Cascione L, Golino G, Riveiro M, Bortolozzi R, Lupia A, Paduano F, Huguet S, Rezai K, Rinaldi A, Margheriti F, Ventura-Aguiar P, Guarda G, Costa G, Rocca R, Furlan A, Verdonk L, Innocenti P, Martin N, Viola G, Driessen C, Zucca E, Stathis A, Gahtory D, Van den Nieuwboer M, Bornhauser B, Alcaro S, Trapasso F, Cristobal S, Padrick S, Pazzi N, Cavalli F, Cavalli A, Gaudio E, Bertoni F. A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers. Haematologica 2024
Jun 20, 2024A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers.
Jun 20, 2024Haematologica 2024
Spriano Filippo, Sartori Giulio, Sgrignani Jacopo, Barnabei Laura, Arribas Alberto, Guala Matilde, Del Amor Ana Maria Carrasco, Tomasso Meagan R, Tarantelli Chiara, Cascione Luciano, Golino Gaetanina, Riveiro Maria E, Bortolozzi Roberta, Lupia Antonio, Paduano Francesco, Huguet Samuel, Rezai Keyvan, Rinaldi Andrea, Margheriti Francesco, Ventura-Aguiar Pedro, Guarda Greta, Costa Giosuè, Rocca Roberta, Furlan Alberto, Verdonk Luuk M, Innocenti Paolo, Martin Nathaniel I, Viola Giampietro, Driessen Christoph, Zucca Emanuele, Stathis Anastasios, Gahtory Digvijay, Van den Nieuwboer Maurits, Bornhauser Beat, Alcaro Stefano, Trapasso Francesco, Cristobal Susana, Padrick Shae B, Pazzi Natalina, Cavalli Franco, Cavalli Andrea, Gaudio Eugenio, Bertoni Francesco
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Adv 2022; 6:3911-3920.
Jul 12, 2022SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Jul 12, 2022Blood Adv 2022; 6:3911-3920
Stathis Anastasios, Mey Ulrich, Schär Sämi, Hitz Felicitas, Pott Christiane, Mach Nicolas, Krasniqi Fatime, Novak Urban, Schmidt Christian, Hohloch Karin, Kienle Dirk, Hess Dagmar, Moccia Alden A, Unterhalt Michael, Eckhardt Katrin, Hayoz Stefanie, Forestieri Gabriela, Rossi Davide, Dirnhofer Stefan, Ceriani Luca, Sartori Giulio, Bertoni Francesco, Buske Christian, Zucca Emanuele, Hiddemann Wolfgang